Literature DB >> 2044637

Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.

Y Chao1, J S Chen, V M Hunt, G W Kuron, J D Karkas, R Liou, A W Alberts.   

Abstract

Lovastatin and simvastatin are potent competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Key inhibit the synthesis of cholesterol in cultured HepG23 cells, rat hepatocytes and in rats. The primary target organ of cholesterol synthesis inhibition by lovastatin and simvastatin is the liver. Lovastating and simvastatin lower levels of plasma cholesterol in rats, dogs and rabbits by inhibition the endogenous cholesterol synthesis and induction of LDL receptor in the liver.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2044637

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  10 in total

1.  Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo.

Authors:  J I Germershausen; V M Hunt; R G Bostedor; P J Bailey; J D Karkas; A W Alberts
Journal:  Biochem Biophys Res Commun       Date:  1989-02-15       Impact factor: 3.575

2.  Secretion of cholesteryl-ester-rich lipoproteins by the perfused livers of rabbits fed a wheat-starch-casein diet.

Authors:  Y S Chao; T T Yamin; J Seidenberg; P A Kroon
Journal:  Biochim Biophys Acta       Date:  1986-05-21

Review 3.  Preclinical evaluation of lovastatin.

Authors:  J S MacDonald; R J Gerson; D J Kornbrust; M W Kloss; S Prahalada; P H Berry; A W Alberts; D L Bokelman
Journal:  Am J Cardiol       Date:  1988-11-11       Impact factor: 2.778

4.  CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species.

Authors:  Y Tsujita; M Kuroda; Y Shimada; K Tanzawa; M Arai; I Kaneko; M Tanaka; H Masuda; C Tarumi; Y Watanabe
Journal:  Biochim Biophys Acta       Date:  1986-06-11

5.  Effect of a new synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on cholesterol synthesis and low density lipoprotein uptake by primary cultures of rat hepatocytes.

Authors:  Y Saito; Y Shiki; K Shirai; S Yoshida
Journal:  Arzneimittelforschung       Date:  1988-02

6.  The effects of mevinolin on serum cholesterol levels of rabbits with endogenous hypercholesterolemia.

Authors:  P A Kroon; K M Hand; J W Huff; A W Alberts
Journal:  Atherosclerosis       Date:  1982-07       Impact factor: 5.162

7.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

8.  Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits.

Authors:  P T Ma; G Gil; T C Südhof; D W Bilheimer; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Regulation of hepatic receptor-dependent degradation of LDL by mevinolin in rabbits with hypercholesterolemia induced by a wheat starch-casein diet.

Authors:  Y S Chao; P A Kroon; T T Yamin; G M Thompson; A W Alberts
Journal:  Biochim Biophys Acta       Date:  1983-11-29

10.  Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog.

Authors:  P T Kovanen; D W Bilheimer; J L Goldstein; J J Jaramillo; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205
  10 in total
  4 in total

Review 1.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

2.  The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076.

Authors:  N J Pearce; J W Yates; T A Berkhout; B Jackson; D Tew; H Boyd; P Camilleri; P Sweeney; A D Gribble; A Shaw; P H Groot
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

3.  Solubility enhancement of lovastatin by modified locust bean gum using solid dispersion techniques.

Authors:  Manjil Patel; Avinash Tekade; Surendra Gattani; Sanjay Surana
Journal:  AAPS PharmSciTech       Date:  2008-12-31       Impact factor: 3.246

Review 4.  Clinical review: Statins and trauma--a systematic review.

Authors:  Jan O Jansen; Janet M Lord; David R Thickett; Mark J Midwinter; Daniel F McAuley; Fang Gao
Journal:  Crit Care       Date:  2013-05-29       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.